Business Trends

Jul 01, 2005
BioPharm International
By BioPharm International Editors
I was playing tennis recently with my friend Ron who, in addition to a wicked backhand, is well-versed in new technologies and gadgets.
Jun 01, 2005
BioPharm International
Utilizing a measured approach can increase the probability for identifying search criteria that fulfill a company’s strategy.
Jun 01, 2005
BioPharm International
As the bustle of Sarbanes-Oxley (SOX) 2004 compliance deadlines for companies winds down, executives have an opportunity to reconsider their company's compliance strategy.
Jun 01, 2005
BioPharm International
By BioPharm International Editors
Our society's penchant for prescription drugs has torn a gaping hole in our collective wallets. According to the US government, overall US health spending has risen to $1.9 trillion in 2005.
May 01, 2005
BioPharm International
By BioPharm International Editors
Conversion of facilities from one use to another is a positive trend that keeps good paying jobs in local communities.
May 01, 2005
BioPharm International
By BioPharm International Editors
Geron rose 7% and StemCells 15% . . . when news of the New York capital funding effort hit the business pages.
May 01, 2005
BioPharm International
Three meetings of the BioPharma Operations Excellence Consortium, facilitated by Tefen Operations Management Consulting, were held recently. The east coast meeting was hosted by Genzyme at its headquarters in Cambridge, MA; the west coast Chapter met at the Genentech campus in South San Francisco, CA; and the European forum held its meeting in Frankfurt, hosted by Aventis.
May 01, 2005
BioPharm International
By BioPharm International Editors
Your company's job is to make biopharmaceutical products. Managing facilities is a function supporting the main task. General manufacturing companies discovered this long ago, but pharmaceutical producers have been lagging. Once you consider the outsouring of non-core activities like facility management (FM), office services, space planning, and utilities management, you can focus on core business functions that make profits.
May 01, 2005
BioPharm International
Cancer remains the primary indication (three products), again mirroring recent approval trends.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Out-licensing has become a crucial part of most biotech companies' business strategies.
native1_300x100
lorem ipsum